The JP Morgan Healthcare Conference is seen as a barometer for the life sciences industry – and, going into this year’s event, the forecast for the year was particularly grim.
People with obesity in Western cultures have largely been subject to shame, blame, stigma, and discrimination that condemns them for their current situation while simultaneously scorning th
There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
